echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Pharmaceuticals submitted a new application for fluorine palli's new adaptive disease for ovarian cancer maintenance treatment

    Hengrui Pharmaceuticals submitted a new application for fluorine palli's new adaptive disease for ovarian cancer maintenance treatment

    • Last Update: 2021-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 28 this year, Hengrui announced that the in-period analysis results of the phase analysis results of the main study endpoint of the phase III clinical (NCT03863860) study compared with placebo for the maintenance treatment of relapsed ovarian cancer reached the optimal standard set by the program.
    a total of 252 subjects in the study were randomly assigned to the group on a 2:1 scale and were treated or orally with fluoroazole parri capsules or fluorine palipari analog capsules, respectively.
    results showed that the single drug treatment of fluoroazole parri significantly prolonged the patient's progression-free survival.
    December 14th, a new drug for the treatment of relapsed ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) with BRCA1/2 mutations was approved by NMPA.
    addition, the treatment of ovarian, breast and pancreatic cancers with fluoroazole pills or co-apatinib is in phase III clinical studies.
    there are a number of other combination therapies, including combination with abitron, combination with the anti-PD-L1 antibody SHR-1316 and temoazine to treat a variety of solid tumors is in clinical development.
    currently has five PARP inhibitors approved for sale in the U.S., Lynparza, Rubraca, Zejula and Talzenna in the U.S., and Olapali in China in August 2018.
    The toluene sulfonate Nirapali capsule, known as Nikolapali, was approved for listing in China in December 2019 for maintenance treatment in adult patients with platinum-sensitive relapsed epithelyl ovarian cancer, fallopian tube cancer or primary peritoneal cancer after platinum-containing chemotherapy has reached full or partial remission.
    2019, Lynparza, Rubraca, Zejula and Talzenna will have global sales of approximately $1,357 million and U.S. sales of approximately $674 million.
    , The cumulative investment in research and development costs of Hengrui Pharmaceutical Fluoropari is about 271.31 million yuan.
    content Source: Medical Rubik's Cube Info
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.